Multiple-dose Safety, Pharmacokinetic and Pharmacodynamic Trial, in Subjects With Allergic Rhinitis
Latest Information Update: 02 Nov 2022
At a glance
- Drugs LU AG09222 (Primary)
- Indications Allergic rhinitis; Grass pollen hypersensitivity
- Focus Adverse reactions
- Sponsors Lundbeck A/S
Most Recent Events
- 25 Oct 2022 Status changed from recruiting to completed.
- 08 Apr 2022 Planned End Date changed from 6 Jun 2022 to 1 Sep 2022.
- 08 Apr 2022 Planned primary completion date changed from 6 Jun 2022 to 1 Sep 2022.